Expert Interview
A second look: Discussing the potential of Zilebesiran, an inhibitor of hepatic angiotensinogen synthesis, in development by Alnylam Pharmaceuticals as an injection for patients with hypertension.
Ticker(s): ALNYInstitution: Atsena Therapeutics
- Manages about 1000 patients with cardiovascilar diseases, of those, about 300 are heart failure patients and 60 patients with Atrial Fibrillation
- Has prescribed Xarelto and Has prescribed to approximately 200 patients.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
